Miki Tateyama
Overview
Explore the profile of Miki Tateyama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
132
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nakatsumi H, Komatsu Y, Harada K, Kawamoto Y, Yuki S, Sawada K, et al.
Int J Cancer
. 2024 Aug;
155(12):2223-2231.
PMID: 39143041
Aflibercept (AFL) plus FOLFIRI prolongs overall survival (OS) in patients with metastatic colorectal cancer (mCRC). However, there is limited evidence on the efficacy and safety of AFL plus FOLFIRI previously...
2.
Harada K, Yamamura T, Muto O, Nakamura M, Sogabe S, Sawada K, et al.
J Clin Med
. 2023 Feb;
12(4).
PMID: 36836140
The effects of gene polymorphisms or prior irinotecan treatment on treatment outcomes of nanoliposomal-irinotecan plus 5-fluorouracil/leucovorin (nal-IRI+5-FU/LV) in patients with unresectable pancreatic ductal adenocarcinoma (PDAC) are not established. This multicenter,...
3.
Nakatsumi H, Komatsu Y, Muranaka T, Yuki S, Kawamoto Y, Harada K, et al.
Front Oncol
. 2022 Nov;
12:939425.
PMID: 36439491
Background: The first-line chemotherapy for patients with and wild-type metastatic colorectal cancer (mCRC) commonly involves cytotoxic regimens, such as FOLFOX and FOLFIRI, combined with epidermal growth factor receptor (EGFR) antibodies....
4.
Nakano S, Kawamoto Y, Yuki S, Harada K, Miyagishima T, Sogabe S, et al.
BMJ Open
. 2022 May;
12(5):e048833.
PMID: 35534074
Introduction: Combination chemotherapy with oxaliplatin, irinotecan, fluorouracil and leucovorin (FOLFIRINOX) has become one of the standard treatments for metastatic pancreatic cancer. However, the use of FOLFIRINOX requires prolonged infusion. Therefore,...
5.
Ito K, Yuki S, Nakatsumi H, Kawamoto Y, Harada K, Nakano S, et al.
Support Care Cancer
. 2022 Mar;
30(6):5351-5359.
PMID: 35292848
Purpose: Dysgeusia is an adverse event caused by chemotherapy. Although retrospective studies have shown zinc administration improves dysgeusia, there have been no prospective studies. The present study examined effects of...
6.
Suda G, Kudo M, Nagasaka A, Furuya K, Yamamoto Y, Kobayashi T, et al.
J Gastroenterol
. 2016 Jan;
51(7):733-40.
PMID: 26768604
Background: HCV infection in chronic hemodialysis patients is high, has a poor prognosis and high risk of renal graft failure, and requires nosocomial infection control measures. However, options of anti-HCV...
7.
Komatsu Y, Okita K, Yuki S, Furuhata T, Fukushima H, Masuko H, et al.
Cancer Sci
. 2015 Apr;
106(7):891-5.
PMID: 25872578
The purpose of this study is to compare the efficacy of a single administration of dexamethasone (DEX) on day 1 against DEX administration on days 1-3 in combination with palonosetron...
8.
Kobayashi Y, Komatsu Y, Yuki S, Fukushima H, Sasaki T, Iwanaga I, et al.
Future Oncol
. 2015 Feb;
11(4):617-27.
PMID: 25686117
Aim: We planned a randomized, open-label trial to evaluate differences between pre-emptive and reactive skin treatment for panitumumab (Pmab)-associated skin toxicities in Japanese patients with metastatic colorectal cancer. Patients &...
9.
Nakatsumi H, Komatsu Y, Yuki S, Sogabe S, Tateyama M, Muto S, et al.
Chemotherapy
. 2013 Feb;
58(6):439-44.
PMID: 23364217
Background: Indisetron is a serotonin (5-hydroxytryptamine type 3) receptor antagonist that also antagonizes 5-hydroxytryptamine type 4 receptors. We designed a pilot study in order to explore the optimal dosing period...
10.
Komatsu Y, Yuki S, Sogabe S, Fukushima H, Nakatsumi H, Kobayashi Y, et al.
Acta Oncol
. 2012 May;
51(7):867-72.
PMID: 22554343
Background: In Japan, a study comparing the effectiveness and safety of irinotecan plus S-1 (IRIS) with those of a combination of 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as second-line treatment in...